- Actinogen Medical (ACW) confirms positive topline results from its XanaMIA Part A trial, meeting primary safety, pharmacodynamic and efficacy endpoints
- Results from the trial confirm Xanamem’s ability to enhance cognition and are consistent with the prior PET dose-ranging study
- The trial was conducted in 107 healthy, cognitively normal, older adults where participants were randomised to receive either 10 milligrams (mg) or five mg doses of Xanamem or matching placebo for a six-week treatment period
- The company will now review detailed results of the XanaMIA Part A trial with academic and industry experts as it finalises the design of its next Alzheimer’s Disease program trial
- Shares in Actinogen Medical are down 4.08 per cent to 9.4 cents as of 12:53 pm AEST
Actinogen Medical (ACW) has confirmed positive topline results from its XanaMIA Part A trial, meeting primary safety, pharmacodynamic and efficacy endpoints.
The XanaMIA Part A dose-ranging trial was conducted in 107 healthy, cognitively normal, older adults with trial participants randomised to receive either 10 milligrams (mg) or five mg doses of Xanamem or matching placebo for a six-week treatment period.
Results from the trial confirm Xanamem’s ability to enhance cognition even in a cognitively normal population and are consistent with the prior PET dose-ranging study which found high levels of Xanamem target occupancy at 5 mg and 10 mg daily doses.
“These results consolidate demonstration of the positive effects of Xanamem on cognition, with excellent safety,” Chief Medical Officer Professor Paul Rolan said.
“They are a major boost to our Alzheimer’s Disease program and open the door to Xanamem’s evaluation in other chronic neurological and psychiatric diseases where poor cognition is a significant complaint.”
CEO and Managing Director Dr Steven Gourlay believes that “Xanamem has the potential to be a novel daily oral therapy for Alzheimer’s Disease and other conditions that could be safely used alone or in combination with other therapies”.
The company will now review detailed results of the XanaMIA Part A trial with academic and industry experts as it finalises the design of its next Alzheimer’s Disease program trial.
Detailed results will be published at a future scientific congress and in a peer reviewed journal.
The XanaMIA Part B trial is planned to study Xanamem’s effects in patients with the early stages of Alzheimer’s disease, using a broadly similar design to that of the Part A trial.
Shares in Actinogen Medical are down 4.08 per cent to 9.4 cents as of 12:53 pm AEST.